Investigational drug · Phase 2
Feladilimab
Also called: GSK3359609
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
9
Any phase or sponsor naming "Feladilimab"
First trial start
2019
Oct 7, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Feladilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Feladilimab" as an intervention, largest first.
GlaxoSmithKlineGSK (GSK)
NCT02723955 · 829 participants · Start Jun 23, 2016 · Primary completion Jul 5, 2023
Drug: feladilimab (GSK3359609); GSK3174998 and 9 more · For: Neoplasms
Sites: Duarte, California; Los Angeles, California; Sarasota, Florida · 28 sites in all
- Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPivotal-lookingTerminated
GlaxoSmithKlineGSK (GSK)
NCT04128696 · 315 participants · Start Nov 21, 2019 · Primary completion Apr 27, 2021
Drug: feladilimab; Pembrolizumab and 1 more · For: Neoplasms, Head and Neck
Sites: Duarte, California; Washington D.C., District of Columbia; St. Petersburg, Florida · 163 sites in all
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Pivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04126200 · 208 participants · Start Oct 7, 2019 · Primary completion Apr 17, 2025
Drug: Belantamab mafodotin; GSK3174998 and 7 more · For: Multiple Myeloma
Sites: Atlanta, Georgia; Indianapolis, Indiana; Boston, Massachusetts · 38 sites in all
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT03739710 · 175 participants · Start Jan 24, 2019 · Primary completion May 2, 2024
Drug: Docetaxel; Feladilimab and 4 more · For: Neoplasms
Sites: Los Angeles, California; St Louis, Missouri; The Bronx, New York · 57 sites in all
- Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPivotal-lookingTerminated
GlaxoSmithKlineGSK (GSK)
NCT04428333 · 117 participants · Start Aug 12, 2020 · Primary completion Apr 27, 2021
Drug: Feladilimab; Pembrolizumab and 3 more · For: Neoplasms, Head and Neck
Sites: Duarte, California; Buenos Aires, Argentina; Oro Verde Entre RIos, Argentina · 71 sites in all
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05553808 · 105 participants · Start Jan 24, 2019 · Primary completion Sep 23, 2021
Drug: Docetaxel; Feladilimab · For: Neoplasms
Sites: St Louis, Missouri; Nashville, Tennessee; Dallas, Texas · 43 sites in all
GlaxoSmithKlineGSK (GSK)
NCT03693612 · 26 participants · Start Nov 26, 2018 · Primary completion Jun 25, 2021
Drug: feladilimab; Tremelimumab and 3 more · For: Neoplasms
Sites: Boston, Massachusetts; New York, New York; Pittsburgh, Pennsylvania · 8 sites in all
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMMActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT07217119 · 25 participants · Start Nov 26, 2019 · Primary completion Apr 17, 2025
Drug: Belantamab mafodotin; Feladilimab · For: Multiple Myeloma
Sites: Atlanta, Georgia; Madison, Wisconsin; Fitzroy, Australia · 11 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06790303 · 8 participants · Start Mar 4, 2021 · Primary completion Sep 23, 2021
Drug: Feladilimab; Ipilimumab · For: Neoplasms
Sites: Nashville, Tennessee; Brampton, Canada; Bordeaux, France
Newest research
PubMed records naming it or its code names, newest first.
- ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.
Garassino MC, Cousin S, Besse B, et al. · Clin Lung Cancer 2026
- INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Rischin D, Hansen AR, Cohen EEW, et al. · Clin Cancer Res 2026
- Advancing ICOS agonism in solid tumors: lessons from INDUCE-1.
Habibzadeh P, Davar D · J Immunother Cancer 2026
- CD28 and ICOS in immune regulation: Structural insights and therapeutic targeting.
Upadhyay S, Kaur B, Gabr MT · Bioorg Med Chem Lett 2025
- First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors.
Maio M, Moreno V, Martin-Liberal J, et al. · J Immunother Cancer 2025
- INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
Hilton JF, Ott PA, Hansen AR, et al. · Cancer Immunol Immunother 2024
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.